Syngene: Shift from CRO to CRAMS to scale up earnings; accumulate Trading Calls - Equity F&O January 22, 2021Recommendations Beyond contract research, another trend to watch for Syngene is the pickup in contract manufacturing business in biologics and APIs Anubhav Sahu
